Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04848519 · ClinicalTrials.gov registry record · Phase 2

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

A Phase 2 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma, sponsored by Emory University.

Active
Registry status
Phase 2
Development phase
6
Enrollment target
1
Study location

NCT04848519: Active Phase 2 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma, sponsored by Emory University.

NCT04848519 is a Phase 2 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma that is active but no longer recruiting, run by Emory University. The registered enrollment target is 6 participants, below the 131-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04848519, a Phase 2 study of Metastatic Urothelial Carcinoma and Locally Advanced Urothelial Carcinoma, is active but no longer recruiting, sponsored by Emory University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This research study is an open label study designed to evaluate the safety and translational correlative changes of the combination of propranolol hydrochloride and immune checkpoint inhibitors (ICI) in subjects with urothelial carcinoma.

Primary Outcome

Assessed according to the Common Terminology Criteria for Adverse Events version 5.0. Descriptive statistics will be used to summarize the toxicity profile of the intervention. Toxicities will be tabulated by grade, association, and cycle number.

Conditions Studied

Metastatic Urothelial Carcinoma Locally Advanced Urothelial Carcinoma Metastatic Bladder Urothelial Carcinoma Locally Advanced Bladder Urothelial Carcinoma Metastatic Ureter Urothelial Carcinoma Metastatic Urethral Urothelial Carcinoma Locally Advanced Ureter Urothelial Carcinoma Metastatic Renal Pelvis Urothelial Carcinoma Locally Advanced Renal Pelvis Urothelial Carcinoma Locally Advanced Urethral Urothelial Carcinoma

Interventions

  • DRUG Pembrolizumab
  • DRUG Nivolumab
  • DRUG Avelumab
  • DRUG Propranolol Hydrochloride

Study Locations (1)

Georgia

  • Emory University Hospital/Winship Cancer Institute - Atlanta

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2021-05-20
Est. Completion 2026-12-04
Phase Phase 2
Emory University

1,208 total trials

What the registry record for NCT04848519 still lists

NCT04848519 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 131-participant average among 30 other Metastatic Urothelial Carcinoma trials with a reported enrollment target (95% lower).

The record links to 10 conditions, with Metastatic Urothelial Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT04848519 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT04848519 about?

NCT04848519 is a clinical study titled "Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma". This research study is an open label study designed to evaluate the safety and translational correlative changes of the combination of propranolol hydrochloride and immune checkpoint inhibitors (ICI) in subjects with urothelial carcinoma.

What is the current status of trial NCT04848519?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2021-05-20. Estimated completion is 2026-12-04.

What conditions does trial NCT04848519 study?

This clinical trial studies the following conditions: Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma.

What interventions are being tested in trial NCT04848519?

The interventions under investigation include: Pembrolizumab (DRUG), Nivolumab (DRUG), Avelumab (DRUG), Propranolol Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT04848519?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04848519 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Urothelial Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04848519's enrollment target sits among peer trials

6 29th of 30 higher than 1 of 30 other Metastatic Urothelial Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Urothelial Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04848519, the US trial registry maintained by the National Library of Medicine. NCT04848519 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.